Merck & Co research closure another blow to Japan
This article was originally published in Scrip
Merck & Cois to close its basic research facility in Tsukuba, Japan by the end of next year, affecting 450 employees. The move forms part of a global restructuring in which similar sites in Rome, Italy, and Seattle in the US will also be shut down over the same timescale.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.